•  
  •  
 

Authors

Flaviu Muresan, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Surgical Department, Cluj-Napoca, RomaniaFollow
Olga Hilda Orasan, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Angela Cozma, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Madalina Daiana Bancos, Iuliu Hatieganu University of Medicine and Pharmacy, Hematology Department, Cluj-Napoca, RomaniaFollow
Lorena Ciumarnean, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Mircea Vasile Milaciu, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Tinca Codruta Pocol, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Nicoleta Valentina Leach, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Teodora Gabriela Alexescu, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Ovidiu Vasile Fabian, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Surgical Department, Cluj-Napoca, RomaniaFollow
George Ciulei, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow
Mirela Georgiana Perne, Iuliu Hatieganu University of Medicine and Pharmacy, 4th Medical Department, Cluj-Napoca, RomaniaFollow

Abstract

Immune checkpoint inhibitors (ICIs) are an effective immunotherapeutic approach for cancers affecting the lung, skin, kidney, mammary gland, or certain hematologic malignancies. Regarding the prognosis of these oncological conditions, treatments with ICIs open new therapeutic perspectives with benefits for both patients and healthcare providers. A drawback of immune checkpoint inhibition is the occurrence of immune-related adverse events that can involve a wide range of organs, such as the liver. Given widespread usage of immunotherapy, the number of patients who suffer from this unwanted condition has increased. Hepatopathy induced by ICIs can be severe and can even lead to death. Detecting liver toxicity in ICIs regiments requires a close monitorization of patients during and after the treatment. Such hepatopathies often involve discontinuation of immune checkpoint inhibitors and administration of corticosteroids. In conclusion, hepatopathies induced by immune checkpoint inhibitors require a comprehensive understanding for effective management, both to protect the patient's life during therapy and to ensure longer survival after cessation of treatment.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS